Takotsubo Syndrome and myasthenia gravis: When neuromuscolar disease meets cardiac dysfunction

Myasthenia gravis (MG) is a neuromuscular autoimmune disease that affects the skeletal muscle through the production of autoantibodies against the nicotinic acetylcholine receptor at the neuromuscular junction, thus causing defective neuromuscular transmission in skeletal muscles [1]. MG occurs in 1: 7500 individuals, affecting women during the second to third decade and men in their fifth and sixth decade of life [2]. Typically, patients experience muscle weakness and fatigue, as well as fluctuating and fatigable extraocular (e.g.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

Myasthenia Gravis (MG), an autoimmune neurological disease, is more frequently found amongst adults than amongst children. Our research provides data on the clinical symptoms, forms of MG, effective treatment, the presence of thymoma and the effect of thymectomy in children with MG in Israel. The database of a tertiary pediatric medical center was retrospectively reviewed for patients under 18 years of age diagnosed between the years 2000-2020 with either ocular or systemic acquired myasthenia gravis.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
AbstractMyasthenia gravis (MG) is an autoimmune disease characterised by the presence of acetylcholine receptor antibodies and by blocking the transmission of the signal in the neuromuscular junction causing muscle weakness. It can be associated with several autoimmune diseases and certain drugs, between them Etanercept an anti-tumour necrosis factor (TNF) agent. A 42-year-old woman with rheumatoid arthritis (RA) refractory to methotrexate, was treated with adalimumab (ADA), a human monoclonal antibody against the TNF, in a dosage scheme of 40  mg every 14 days subcutaneously. The patient responded well to ADA th...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
AbstractMyasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling weakness through a compromise of neuromuscular transmission. The disease fulfills strict criteria of an antibody-mediated disease. Close to 90% of patients have antibodies directed towards the nicotinic acetylcholine receptor (AChR) on the post-synaptic surface of skeletal muscle and another 5% to the muscle-specific kinase, which is involved in concentrating the AChR to the muscle surface of the neuromuscular junction. Conventional treatments of intravenous immunoglobulin and plasma exchange reduce autoantibody levels to produc...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
In conclusion, different subtypes of MG harbored differential gut microbiota, which generated discriminative fecal metabolism.
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conclusion: The coexistence of SS with MG is quite rare. The onset of MG may occur before or after the diagnosis of SS. Co-morbidity with MG does not seem to adversely affect the course of SS. Thus, controlling the progress of MG is the critical aspect of treatment.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Abstract Myasthenia gravis is a rare and invalidating disease affecting the neuromuscular junction of voluntary muscles. The classical form of this autoimmune disease is characterized by the presence of antibodies against the most abundant protein in the neuromuscular junction, the nicotinic acetylcholine receptor. Other variants of the disease involve autoimmune attack of non-receptor scaffolding proteins or enzymes essential for building or maintaining the integrity of this peripheral synapse. This review summarizes the participation of the above proteins in building the neuromuscular junction and the destructio...
Source: Biomed Res - Category: Research Authors: Tags: Neural Regen Res Source Type: research
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that block or destroy nicotinic acetylcholine receptors at the neuromuscular junction. Most of MG patients need immunosuppression agents in ...
Source: BMC Neurology - Category: Neurology Authors: Tags: Case report Source Type: research
Abstract Myasthenia gravis (MG) is an autoimmune disease in which Abs target neuromuscular junction proteins, in particular the acetylcholine receptor. We previously identified the antiapoptotic protein survivin in the autoreactive B cells and plasma cells of MG patients. To further define the role of survivin in MG, we have assessed PBMCs from 29 patients with MG and 15 controls. We confirmed the increased expression of survivin in CD20+ lymphocytes from MG patients compared with controls. Furthermore, the CD20+ population of cells from MG patients contained a higher percentage of extracellular survivin compared ...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
CONCLUSION: Type II fiber atrophy and type II fiber predominance may often be found in patients with LEMS associated with SCLC. Also, scattered fiber necrosis may appear in this disease. PMID: 32831159 [PubMed - as supplied by publisher]
Source: Clinical Neuropathology - Category: Pathology Authors: Tags: Clin Neuropathol Source Type: research
More News: Autoimmune Disease | Brain | Cardiology | Heart | Myasthenia Gravis | Neurology | Women